›› 2014, Vol. 41 ›› Issue (9): 47-51.

Previous Articles     Next Articles

Study on Preparation of Rabbit Anti-canine Parvovirus Type 2a Polyclonal Antibody

LI Si-qi1,2, PENG Guang-neng1   

  1. 1. Animal Disease and Human Health Key Laboratory of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Ya'an 625014, China;
    2. Department of Animal Science and Technology, Chongqing Three Gorges Vocational College, Chongqing 404155, China
  • Received:2014-02-24 Online:2014-09-20 Published:2014-09-24

Abstract: To study the antigenic relationship among the original canine parvovirus type (CPV) 2 (CPV-2) and the variants CPV-2a,the strain of 105 TCID50/100 μL from infected Tibetan mastiff which turns out the gene was CPV-2a and CPV-2 strain from vaccine was picked out to be generally amplified in the F81 cells. After analyzing the strains with HA and protein concentration with PEG6000, the viral suspension was emulsified with the adjuvant to immune two groups of each three New Zealand rabbits in every two weeks and four times. Serum antibody titer was detected in each preimmune. After four times immunity, serum of each group was collected to make separated gene polyclonal antibody. Then the antibody titer was tested by SN and HI with CPV-2 and CPV-2a virus and protection data was analyzed by SPSS 17.0. And two polyclonal antibodies were separated treated 2 dogs which was inoculation CPV-2a and infected. Blood samples were collected every day during treatment,then WBC was analyzed by SPSS 17.0. The results showed that the CPV-2a polyclonal antibody was more significant to CPV-2a virus than the other one by HI and SN (P<0.01).But counteract CPV-2 strain was not significant (P>0.05). CPV-2a polyclonal antibody was given more protection against CPV-2a and WBC was faster recovery to normal level than the other in experimental treatment (P<0.05).It showed that CPV-2a polyclonal antibody have higher homologous protection than the antibody induced by CPV-2 vaccine in Chinese canine parvovirus control.

Key words: polyclonal antibody; CPV-2a; CPV-2; cross protection

CLC Number: